Find a Biotech job in Boston

Two biotech projects seek Lexington Town Meeting approval

Two large development proposals that could boost Lexington’s growing reputation as a home for biotechnology are about to come up for a vote. (Boston Globe, 11/7/09)

New label says Tysabri risks increase over time

NEW YORK - A brain infection linked to Biogen Idec Inc. and Elan Corp.’s Tysabri is more likely to occur the longer patients use the multiple sclerosis drug, new prescribing information says. (Boston Globe, 11/6/09)

Local biotech firm wins OK on cancer drug

Gloucester Pharmaceuticals, a six-year-old Cambridge biotechnology start-up, has won approval from the Food and Drug Administration to market its first drug in the United States. (Boston Globe, 11/6/09)

Lexington’s Pulmatrix raises $30m

Pulmatrix has raised $30 million to help the Lexington biotechnology company develop treatments for respiratory illnesses, according to a release from the company. (Boston Globe, 11/2/09)

Genzyme plant gets agency approval

Genzyme Corp. said it has received correspondence from the European Medicines Agency, the main drug regulatory agency for Europe, finding the Cambridge biotechnology company’s Allston plant “in general compliance with the principles and guidelines of good manufacturing practice.’’ (Boston Globe, 11/2/09)